GTx says that an interim analysis of late-stage data on Acapodene shows that the drug lowered the level of bad cholesterol and raised the level of good cholesterol. Earlier data indicates that the experimental therapy increases bone mineral density. The drug is being studied to see if it reduces fractures among patients with prostate cancer. The trial included 197 subjects who have completed a year of dosing. Researchers believe the drug can help prevent the serious side effects associated with androgen deprivation therapy and are projecting a 40 percent reduction in fractures over two years.
"Acapodene has demonstrated the potential to increase bone mineral density, and the lipid interim analysis suggests that Acapodene may lower cholesterol," said Mitchell S. Steiner, M.D., CEO of GTx. "We continue to be confident in the Phase III ADT clinical trial. If Acapodene can treat multiple serious side effects of ADT, it has the potential to become the mainstay of prostate cancer supportive care for patients on ADT."
- here's the release on Acapodene